|Title:||Oral dosage form for treating migraine|
|Abstract:||A pharmaceutical composition for oral adminstration comprising a film-coated solid dosage form including 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide or a pharmaceutically acceptable salt or solvate thereof as active ingredient. The film-coated solid dosage forms are of use in the treatment of conditions associated with cephalic pain, in particular migraine.|
|Inventor(s):||Phillips; Anthony John (Ware, GB3), Winterborn; Ian Keith (Mississauga, CA), Padfield; John Malcolm (Uxbridge, GB3)|
|Assignee:||Glaxo Group Limited (Greenford, GB2)|
Patent Claim Types:|
see list of patent claims
|Composition; Compound; Dosage form; Use;|
|Patent Number||Expiration Date|
|5,863,559||January 26, 2007|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Georgia, Republic of||P20012549||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.